FAIRBANKS PHARMACEUTICALS

Biotech · Private

Small-molecule FSTL3 antagonist compounds that enhance α- to β-cell transdifferentiation to restore insulin-producing capacity in diabetes

Grants
$2.0M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
1 granted · 2 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Development Of Novel Diabetes Therapies Based On Neutralizing FSTL3 Activity$192,101
Federal grantDepartment of Health and Human Services · Phase II · Development Of Novel Diabetes Therapies Based On Neutralizing FSTL3 Activity$920,248
Federal grantDepartment of Health and Human Services · Phase II · Development Of Novel Diabetes Therapies Based On Neutralizing FSTL3 Activity$911,260
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1591THERANOSTEC INC——
1592KURE. AI, INC.——
1593INSILICOS——
1594FAIRBANKS PHARMACEUTICALS——
1595Resonate Industries Inc—$555K
1596Algen Biotechnologies Inc——
1597Novear Therapeutics LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 3

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.